Last reviewed · How we verify
DAR-100A
At a glance
| Generic name | DAR-100A |
|---|---|
| Sponsor | New York State Psychiatric Institute |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders (EARLY_PHASE1)
- Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAR-100A CI brief — competitive landscape report
- DAR-100A updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI